Clinicopathological features and possible prognostic factors in parotid lymphomas

  • Qian SU ,
  • Xin PENG ,
  • Chuan-xiang ZHOU ,
  • Guang-yan YU
Expand
  • 1. Department of Oral and Maxillofacial Surgery, Beijing 100081, China
    2. Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China

Received date: 2018-10-15

  Online published: 2019-02-26

Abstract

Objective: To investigate the clinicopathological features and prognostic factors in lymphoma of parotid origin. Methods: Clinicopathological data of the patients with parotid lymphoma who were initially diagnosed in Peking University Hospital of Stomatology from 2006 to 2016 were collected and analyzed retrospectively. The patients were followed-up for 5 to 149 months with a median period of 45 months, and the factors influencing the prognosis were evaluated. Results: A total of 41 patients with primary parotid lymphoma were included in this retrospective study. The rate of male to female was 1 ∶2.15. The median age was 57 years (ranging from 8 months to 91 years). According to WHO classification, 40 cases (97.1%) were diagnosed as non-Hodgkin lymphoma (NHL), including 15 cases of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), 14 cases of diffuse large B cell lymphoma (DLBCL) as well as 4 cases of follicular lymphoma, while other subtypes of NHL were rare. Only one case was diagnosed as Hodgkin lymphoma. Regarding the clinical staging at the initial diagnosis, 37 patients (90.2%) were diagnosed as stage ⅠE or ⅡE of the disease, while 4 patients (9.8%) as stage ⅢE or stage ⅣE. Seven patients (17.1%) had a history of Sjögren syndrome (SS), all of whom were MALT lymphoma. The mean ill duration of the 41 patients were 20.7 months. Thirty-two patients (78%) presented a slowly growing painless mass in the parotid gland. Treatment options included localized therapy and systemic therapy, all of whom had good curative effect. Nine patients (21.9%) died during the follow-up period. The overall survival rates of 2-year and 5-year were 84.5% and 81.3% respectively. The univariate analysis demonstrated statistically significant differences for accelerated growth of tumor (P=0.005), and presence of tumor capsule (P=0.011). The multi-univariate analysis demonstrated statistically significant differences for presence of tumor capsule (P=0.041). Conclusion: A large majority of primary parotid lymphoma were NHL, among which MALT lymphoma and DLBCL were common subtypes. Most patients presented an indolent mass in parotid gland, which should be distinguished from the parotid benign tumors. SS is closely related to the pathogenesis of MALT lymphoma. The prognosis is better than that of other malignant parotid tumors. Absence of tumor capsule may predict a poor prognosis in patients with parotid lymphoma.

Cite this article

Qian SU , Xin PENG , Chuan-xiang ZHOU , Guang-yan YU . Clinicopathological features and possible prognostic factors in parotid lymphomas[J]. Journal of Peking University(Health Sciences), 2019 , 51(1) : 35 -42 . DOI: 10.19723/j.issn.1671-167X.2019.01.007

References

[1] 陈万青, 郑荣寿, 张思维 , 等. 2013年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2017,26(1):1-7.
[2] 李小秋, 李甘地, 高子芬 , 等. 中国淋巴瘤亚型分布:国内多中心性病例10 002例分析[J]. 诊断学理论与实践, 2012,11(2):111-115.
[3] Urquhart A, Berg R . Hodgkin’s and non-Hodgkin’s lymphoma of the head and neck[J]. Laryngoscope, 2001,111(9):1565-1569.
[4] Etemad-Moghadam S, Tirgary F, Keshavarz S , et al. Head and neck non-Hodgkin’s lymphoma: a 20-year demographic study of 381 cases[J]. Int J Oral Max Surg, 2010,39(9):869-872.
[5] Swerdlow SH, Campo E, Harris NL , et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. 4th ed. Iyon: International Agency for Research on Cancer, 2017.
[6] Skarin AT, Dorfman DM . Non-Hodgkin’s lymphomas: Current classification and management[J]. CA Cancer J Clin, 1997,47(6):351-372.
[7] Gleeson MJ, Bennett MH, Cawson RA . Lymphomas of salivary glands[J]. Cancer, 1986,58(3):699-704.
[8] El-Naggar AK, Chan JKC, Grandis JR , et al. WHO classification of head and neck tumors[M]. 4th ed. Lyon: International Agency for Research on Cancer, 2017: 276-280.
[9] Feinstein AJ, Ciarleglio MM, Cong X , et al. Parotid gland lymphoma: prognostic analysis of 2140 patients[J]. Laryngoscope, 2013,123(5):1199-1203.
[10] Vazquez A, Khan MN, Sanghvi S , et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009[J]. Head Neck, 2015,37(1):18-22.
[11] Isaacson P, Wright DH . Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma[J]. Cancer, 1983,52(8):1410-1416.
[12] 徐鹏程, 周心一, 周晨 , 等. 腮腺黏膜相关淋巴组织淋巴瘤的临床特点分析[J]. 临床耳鼻咽喉头颈外科杂志, 2017(1):61-64.
[13] Ambrosetti A, Zanotti R, Pattaro C , et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associa-ted either with Sjögren syndrome or hepatitis C virus infection[J]. Br J Haematol, 2004,126(1):43-49.
[14] Dong L, Chen Y, Masaki Y , et al. Possible mechanisms of lymphoma development in Sjögren’s syndrome[J]. Curr Immunol Rev, 2013,9(1):13-22.
[15] Zhang W, Feng S, Yan S , et al. Incidence of malignancy in primary Sjögren’s syndrome in a Chinese cohort[J]. Rheumatology (Oxford), 2010,49(3):571-577.
[16] Theander E, Henriksson G, Ljungberg O , et al. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors[J]. Ann Rheum Dis, 2006,65(6):796-803.
[17] 卢松鹤, 闫志敏, 魏明洁 , 等. 结节型舍格伦综合征与恶性淋巴瘤关系初探[J]. 中华口腔医学杂志, 2012,47(4):208-213.
[18] Peveling-Oberhag J, Arcaini L, Bankov K , et al. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis[J]. J Viral Hepat, 2016,23(7):536-544.
[19] Arcaini L, Rossi D, Lucioni M , et al. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection[J]. Haematologica, 2015,100(2):246-252.
[20] Brito-Zerón P, Gheitasi H, Retamozo S , et al. How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients[J]. Arthritis Res, 2015,17(1):1-9.
[21] Raderer M, Kiesewetter B, Ferreri AJ . Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)[J]. CA Cancer J Clin, 2016,66(2):153-171.
[22] Swerdlow SH, Campo E, Pileri SA , et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016,127(20):2375-2390.
[23] Thielker J, Grosheva M, Ihrler S , et al. Contemporary management of benign and malignant parotid tumors[J]. Front Surg, 2018,39(5):1-17.
[24] Gudmundsson JK, Ajan A, Abtahi J . The accuracy of fine-needle aspiration cytology for diagnosis of parotid gland masses: a clinicopathological study of 114 patients[J]. J Appl Oral Sci, 2016,24(6):561-567.
[25] Orita Y, Sato Y, Kimura N , et al. Characteristic ultrasound features of mucosa-associated lymphoid tissue lymphoma of the salivary and thyroid gland[J]. Acta Otolaryngol, 2014,134(1):93-99.
[26] 高润涛, 耿雪霏 . 8例腮腺恶性淋巴瘤诊疗体会[J]. 口腔医学研究, 2017,33(8):870-873.
[27] Olszewski AJ, Desai A . Radiation therapy administration and survival in stage Ⅰ/Ⅱ extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue[J]. Int J Radiat Oncol Biol Phys, 2014,88(3):642-649.
[28] Jackson AE, Mian M, Kalpadakis C , et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41)[J]. Oncologist, 2015,20(10):1149-1153.
[29] Salles G, Barrett M, Foa R , et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience[J]. Adv Ther, 2017,34(10):2232-2273.
[30] 傅志英, 朱军, 宋玉琴 , 等. 525例弥漫大B细胞淋巴瘤预后影响因素分析[J]. 北京大学学报(医学版), 2014,46(3):405-411.
[31] 杨小芸, 沈丽达, 龙庭凤 , 等. 1 326例非霍奇金淋巴瘤临床病理特点分析[J]. 中华肿瘤防治杂志, 2016,23(9):605-609.
Outlines

/